Oral small molecules for the treatment of atopic dermatitis: a systematic review
- 2 December 2018
- journal article
- review article
- Published by Taylor & Francis in Journal of Dermatological Treatment
- Vol. 30 (6) , 550-557
Abstract
Introduction: Atopic dermatitis (AD) is a chronic, inflammatory skin disease. Conventional treatments include topical emollients, corticosteroids, calcineurin inhibitors, phototherapy, and systemic immunomodulatory agents, however, these medications have limitations in the treatment of moderate to severe AD. Current literature demonstrates that oral small molecules may be an effective modality to treat AD. Method: Using PubMed/MEDLINE, Embase, Cochrane Skin databases and clinicaltrials.gov a search with terms ‘atopic dermatitis or atopic eczema’ and ‘name of the oral small molecule’ was conducted resulting in 1197 articles. Inclusion criteria were studies involving human subjects treated with oral small molecule medication for AD and written in English. Randomized clinical trials, open-label prospective trials, and case reports/series were reviewed. Results: Seven articles, with a total of 250 patients, were included for review. Oral small molecules studied include: apremilast, baricitinib, JNJ-39758979, and tofacitinib. Small molecules demonstrate improvement in AD disease scores, patient-reported outcomes, and quality of life. Conclusion: Preliminary results demonstrate that oral small molecules are an effective treatment option in AD with minimal side effects. Additional randomized studies with larger sample sizes are needed to determine the efficacy and long-term side effects of these novel therapies.Keywords
This publication has 49 references indexed in Scilit:
- The involvement of the JAK-STAT signaling pathway in chronic inflammatory skin disease atopic dermatitisJAK-STAT, 2013
- Phosphodiesterase 4 Inhibition in the Treatment of Psoriasis, Psoriatic Arthritis and Other Chronic Inflammatory DiseasesDermatology and Therapy, 2013
- Apremilast, a cAMP phosphodiesterase‐4 inhibitor, demonstrates anti‐inflammatory activity in vitro and in a model of psoriasisBritish Journal of Pharmacology, 2010
- Histamine H4receptor antagonist ameliorates chronic allergic contact dermatitis induced by repeated challengeAllergy, 2010
- Systemic Treatment of Severe Atopic Eczema: A Systematic ReviewActa Dermato-Venereologica, 2007
- The phosphodiesterase 4 inhibitor AWD 12–281 is active in a new guinea-pig model of allergic skin inflammation predictive of human skin penetration and suppresses both Th1 and Th2 cytokines in miceJournal of Pharmacy and Pharmacology, 2005
- Randomized comparison of the type 4 phosphodiesterase inhibitor cipamfylline cream, cream vehicle and hydrocortisone 17-butyrate cream for the treatment of atopic dermatitisBritish Journal of Dermatology, 2002
- Suppression of granulocyte/macrophage colony‐stimulating factor release from human monocytes by cyclic AMP‐elevating drugs: role of interleukin‐10British Journal of Pharmacology, 2001
- Immunochemical characterization of the distinct monocyte cyclic AMP-phosphodiesterase from patients with atopic dermatitisJournal of Allergy and Clinical Immunology, 1993
- Elevated leukocyte cyclic AMP—phosphodiesterase in atopic disease: a possible mechanism for cyclic AMP—agonist hyporesponsivenessJournal of Allergy and Clinical Immunology, 1982